付纪军 教授

教育经历

2011年至2014年  北京大学  药剂学博士

2008年至2011年  沈阳药科大学  药剂学硕士

2004年至2008年  中国药科大学  国家生命科学与技术基地班 学士

工作经历

2016年至今  广州医科大学  副教授

2015年      南方科技大学  生物系Research Fellow

【联系邮箱】

fujj@gzhmu.edu.cn

欢迎愿意开展药剂学研究的本科生进入实验室学习！

【研究方向】

研究方向是药剂学，主要研究领域是纳米药物递送系统，包括超分子纳米载体、纳米诊疗系统、CT/MRI造影剂等。

【主要科研项目】

国家自然科学基金青年项目，基于细胞毒性药物5-FU在肿瘤局部产生原理的前药代谢酶基因CDUPRT脂质体用于乳腺癌靶向化疗（81803463），主持。

【所获荣誉和奖励】

【主要论文及著作（代表性）】

1 Nano-drug delivery systems, such as biomimetic delivery system, photothermal therapy against cancer and injectable hydrogel. In details, I have carried out research in biomimetic delivery systems by using macrophages as the carrier of anti-cancer drugs. The influence of the enhanced permeability and retention effects on the tumor distribution of nanoparticles was also investigated. I also do research in nanoparticles in cancer theranostics, such as photothermal, photodynamic, thermodynamic and small molecular CT contrast agent. Supermolecular nano-vehicles and microneedles for transdermal application are also investigated. Publications:

(1) Jiexia Li^#; Lingmin Zhang^#; Chengcheng Liu^#; Qianni Wu; Songpei Li; Xueping Lei; Yugang Huang; Guining Feng; Xiyong Yu; Xianqiang Sun; Zhaoming Guo^*; Jijun Fu^*; Doxorubicin-loaded hydrogen peroxide self-providing copper nanodots for combination of chemotherapy and acid-induced chemodynamic therapy against breast cancer, Journal of Colloid and Interface Science. Accept   I. F. 7.489

(2) Ji-jun Fu^#; Chu-wen Li^#; Yang Liu^#; Ming-yue Chen; Qiang Zhang; Xi-yong Yu; Bo Wu; Jie-xia Li; Ling-ran Du; Yuan-ye Dang; Dan Wu; Min-yan Wei^*; Zhi-qiang Lin^*; Xue-ping Lei^*; The microneedles carrying cisplatin and IR820 to perform synergistic chemo photodynamic therapy against breast cancer, Journal of Nanobiotechnology, 2020, 18(1): 146.  I. F. 6.518

(3) Jijun Fu^#; Dan Wang^#; Dong Mei; Haoran Zhang; Zhaoyang Wang; Bing He; Wenbing Dai; Hua Zhang; Xueqing Wang; Qiang Zhang^*; Macrophages mediated biomimetic delivery system for the treatment of lung metastasis of breast cancer, Journal of Controlled Release, 2015, 204: 11-19.   I. F. 7.727

(4) Ming-yue Chen^#; Ze-kuan Xiao^#; Xue-ping Lei^#; Jie-xia Li; Xi-yong Yu; Jian-ye Zhang; Guo-dong Ye; Yu-juan Guo; Guangquan Mo; Chu-wen Li; Yu Zhang; Ling-min Zhang^*; Zhi-qiang Lin^*; Ji-jun Fu^*; Preparation, characterization and in vitro–in vivo evaluation of bortezomib supermolecular aggregation nanovehicles, Journal of Nanobiotechnology, 2020, 18(1): 57.  I. F. 6.518

(5) Yanfen Zhang^#; Yuyan Qin^#; Huan Li^#; Qingsheng Peng; Ping Wang; Langyu Yang; Sheng Chen; Ming Li; Jijun Fu^*; Xiyong Yu^*; Lingmin Zhang^*; Artificial Platelets for Efficient siRNA Delivery to Clear “Bad Cholesterol”, ACS Applied Materials & Interfaces, 2020, 12(25): 28034-28046.   I. F. 8.758

(6) Fu Jijun; Wu Bo; Wei Minyan; Huang Yugang; Zhou Yi; Zhang Qiang^*; Du Lingran^*; Prussian blue nanosphere-embedded in situ hydrogel for photothermal therapy by peritumoral administration, Acta Pharmaceutica Sinica B, 2019, 9(3): 604-614.  I. F. 7.097

(7) Dan Wang^#; Jijun Fu^#; Yujie Shi; Dong Peng; Lan Yuan; Bing He; Wenbing Dai; Hua Zhang; Xueqing Wang; Jie Tian; Qiang Zhang^*; The modulation of tumor vessel permeability by thalidomide and its impacts on different types of targeted drug delivery systems in a sarcoma mouse model, Journal of Controlled Release, 2016, 238: 186-196.  I. F. 7.727

2 Cancer molecular biology, such as RNA helicase DHX33 and micro-RNA. In details, by using the techniques of CHIP, luciferase assay, EMSA, RNA knock down, we demonstrated that c-myc bind to the DHX33 promoter and induced cancer progress. Publications:

(1) Lu Liang^#; Jijun Fu^#; Siran Wang^#; Huiyu Cen; Lingmin Zhang; Safur Rehman Mandukhail; Lingran Du; Qianni Wu; Peiquan Zhang^*; Xiyong Yu^*; MiR-142-3p enhances chemosensitivity of breast cancer cells and inhibits autophagy by targeting HMGB1, Acta Pharmaceutica Sinica B, 2020, 10(6): 1036-1046.   I. F. 7.097

(2) Jijun Fu^#; Yuchu Liu^#; Xingshun Wang; Baolei Yuan; Yandong Zhang^*; Role of DHX33 in c-myc-induced cancers, Carcinogenesis, 2017, 38(6): 649-660.   I. F. 4.603

(3) Chuanyue Wu^#*; Jin You^#; Jijun Fu^#; Xingshun Wang; Yandong Zhang^*; PI3K/Akt mediates integrin signaling to control RNA polymerase I transcription, Molecular and Cellular Biology, 2016, 36(10): 1555-1568.   I. F. 3.611

3 Industrial pharmaceutics, such as microspheres, solid dispersions (SD) of insoluble drugs and sustained release formulations. In details, in order to increase the dissolution and oral bioavailability of nimodipine, the solid dispersion of the drug was prepared by hot-melt extrusion and, the SD was successfully formulated into tablets. In this process, the SD was characterized by X-ray, DSC et al. How to inhibit drug recrystallization in the release media is the most difficult, and the problem was successfully solved five years later. Actually, in this process, we have summarized some principles which could be applied to other insoluble drugs. I also prepared the sustained release pellets of diclofenac potassium. For both drugs, we applied for New Drug Application from China Food and Drug Administration (CFDA). Publications:

(1) Yang Liu^*; Yanna Chen; Xingli Gao; Jijun Fu^*; Liandong Hu^*; Application of cyclodextrin in food industry, CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION, 2020.   I. F. 7.862

(2) Min-yan Wei^#; Xue-ping Lei^#; Jing-jing Fu^#; Ming-yue Chen; Jie-xia Li; Xi-yong Yu; Yin-lei Lin; Jing-ping Liu; Ling-ran Du; Xin Li; Yu Zhang; Ying-ling Miao; Yu-gang Huang^*; Lu Liang^*; Ji-jun Fu^*; The use of amphiphilic copolymer in the solid dispersion formulation of nimodipine to inhibit drug crystallization in the release media: Combining nano-drug delivery system with solid preparations, Materials Science & Engineering C, 2020, 111: 110836.   I. F. 5.880

(3) Ji-jun Fu^#*; Jun-jie Guo^#; Ai-ping Qin^#; Xi-yong Yu; Qiang Zhang; Xue-ping Lei; Yu-gang Huang; Ming-yue Chen; Jie-xia Li; Yu Zhang; Jing-ping Liu; Yuan-ye Dang; Dan Wu; Xiao-ya Zhao; Zhong-xiao Lin; Yin-lei Lin; Song-pei Li^*; Ling-yan Zhang^*; Bismuth chelate as a contrast agent for X ray computed tomography, Journal of Nanobiotechnology, 2020, 18(1): 110.   I. F. 6.518

(4) Lingran Du; Yugang Huang; Qiang Zhang; Yi Zhou; Jianwen Huang; Libiao Yan; Zongjun Yu; Aiping Qin; Hainan Yang; Mianrong Chen; Lu Liang; Biyun Bian; Xufeng Li^*; Jijun Fu^*; Synthesis and assessment of drug-eluting microspheres for transcatheter arterial chemoembolization, Acta Biomaterialia, 2019, 88: 370-382.   I. F. 7.242

(5) Jijun Fu; Chengcheng Liu^*; Tri-block polymer with interfacial layer formation ability and its use in maintaining supersaturated drug solution after dissolution of solid dispersions, International Journal of Nanomedicine, 2018, 13: 1611-1619.   I. F. 5.115

(6) Jijun Fu; Xiaoli Wang; Lishuang Xu; Jia Meng; Yan Weng; Guofei Li; Haibing He; Xing Tang^*; Preparation and in vitro-in vivo evaluation of double layer coated and matrix sustained release pellet formulations of diclofenac potassium, International Journal of Pharmaceutics, 2011, 406: 84-90.   I. F. 4.845

(7) Jijun Fu; Lili Zhang; Tingting Guan; Xing Tang^*; Haibing He; Stable nimodipine tables containing NM-SD prepared by hot-melt extrusion, Powder Technology, 2010, 204: 214-221.   I. F. 4.142

(8) Jijun Fu; Lishuang Xu; Xiaoguang Tao; Min Su; Mingming Zhao; Haibing He; Xing Tang^*; The inhibition effect of high storage temperature on the recrystallization rate during dissolution of Nimodipine-Kollidon VA64 solid dispersions (NM-SD) prepared by hot-melt extrusion, Journal of Pharmaceutical Sciences, 2011, 100(5): 1643-1647.   I. F. 2.997

(9) Jijun Fu; Lishuang Xu; Xiaoli Wang; Shu Zhang; Xiaoguang Tao; Xingna Zhao; Haibing He; Xing Tang^*; Nimodipine (NM) tablets with high dissolution containing NM solid dispersions prepared by hot-melt extrusion, Drug Development and Industrial Pharmacy, 2011, 37(8): 934-944.   I. F. 2.365